CLAIMS

1. Use of a peptide in the manufacture of a medicament for minimising the progression of cancer in an individual by forming an immune response in the individual to a P2X7 receptor, wherein the cancer in the individual has been reduced in size, mass or other physical measure by the administration of a non self antigen binding site for the treatment of cancer, wherein the peptide comprises the amino acid sequence GHNYTTRNILPGLNITC.

2. Use of claim 1, wherein the individual does not have detectable non self antigen binding sites in circulation.

3. Use of claims 1, wherein the individual does not have detectable cancer.

4. Use of claim 3, wherein the individual has developed an immune response to the non self antigen binding site.

5. Use of claim 1, wherein the individual has received a non self antigen binding site that binds to non-functional $P2X_7$ receptor, but not to functional $P2X_7$ receptor, for treatment of the cancer.

6. Use of claim 1, wherein the non self antigen binding site received by the individual for treatment of the cancer does not bind to a $P2X_7$ receptor, or a fragment of a $P2X_7$ receptor.

7. Use of claim 1, wherein the peptide is provided in an initial administration to the individual, thereby forming a response that includes IgM production in the individual.

8. Use of claim 1, wherein the peptide is provided in an initial administration to the individual, thereby forming a response that includes IgM production, and at a later time, in a further administration to the initial administration, thereby forming a response that includes IgG production.

9. Use according to claim 6, wherein the non self antigen binding site or anti-cancer antigen antibody is selected from the group consisting of a dAb, Fab, Fd, Fv, $F(ab')_2$, scFv and CDR.

10. Use of an immunogen in the form of a cancer-associated $P2X_7$ receptor or fragment thereof in the manufacture of a medicament for forming a humoral immune response to cancer-

associated $P2X_7$ receptors in an individual who has received an anti-cancer antigen antibody for therapy of cancer,

wherein the immune response is formed in the individual at a time where anti-cancer antigen antibody administered for treatment of cancer is at a level or concentration that is substantially undetectable in the individual; and/or

the humoral immune response to cancer –associated $P2X_7$ receptors is formed according to an immunisation schedule whereby the amount of antibody formed in the individual to cancer-associated $P2X_7$ receptor is about 0.1 to 25 mg/kg individual,

wherein the cancer in the individual has been reduced in size, mass or other physical measure by the administration of the non self antigen binding site.

11. Use according to claim 10, wherein the non self antigen binding site or anti-cancer antigen antibody is selected from the group consisting of a dAb, Fab, Fd, Fv, $F(ab')_2$, scFv and CDR.

12. Use according to claim 11, wherein the fragment of a $P2X_7$ receptor has an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 3 and 4.

13. Use according to claim 1 or 10, wherein the cancer is selected from the group consisting of adenocarcinoma, adenoma, adenofibroma, adenolymphoma, adontoma, AIDS related cancers, acoustic neuroma, acute lymphocytic leukemia, acute myeloid leukemia, adenocystic carcinoma, adrenocortical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft-part sarcoma, ameloblastoma, angiokeratoma, angiolymphoid hyperplasia with eosinophilia, angioma sclerosing, angiomatosis, apudoma, anal cancer, angiosarcoma, aplastic anaemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma (skin), bladder cancer, bone cancers, bowel cancer, brain stem glioma, brain and CNS tumors, breast cancer, branchioma, CNS tumors, carcinoid tumors, cervical cancer, childhood brain tumors, childhood cancer, childhood leukemia, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancers, cutaneous T-cell lymphoma, carcinoma (e.g. Walker, basal cell, basosquamous, Brown-Pearce, ductal, Ehrlich tumor, Krebs 2, Merkel cell, mucinous, non-small cell lung, oat cell, papillary, scirrhous, bronchiolar, bronchogenic, squamous cell, and transitional cell), carcinosarcoma, cervical dysplasia, cystosarcoma phyllodies, cementoma, chordoma, choristoma, chondrosarcoma, chondroblastoma,

craniopharyngioma, cholangioma, cholesteatoma, cylindroma, cystadenocarcinoma, cystadenoma, dermatofibrosarcoma- protuberans, desmoplastic-small-round-cell-tumor, ductal carcinoma, dysgerminoam, endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extra-hepatic bile duct cancer, eye cancer, eye: melanoma, retinoblastoma, fallopian tube cancer, fanconi anaemia, fibroma, fibrosarcoma, gall bladder cancer, gastric cancer, gastrointestinal cancers, gastrointestinal-carcinoid-tumor, genitourinary cancers, germ cell tumors, gestationaltrophoblastic-disease, glioma, gynaecological cancers, giant cell tumors, ganglioneuroma, glioma, glomangioma, granulosa cell tumor, gynandroblastoma, haematological malignancies, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hereditary breast cancer, histiocytosis, Hodgkin's disease, human papillomavirus, hydatidiform mole, hypercalcemia, hypopharynx cancer, hamartoma, hemangioendothelioma, hemangioma, hemangiopericytoma, hemangiosarcoma, hemangiosarcoma, histiocytic disorders, histiocytosis malignant, histiocytoma, hepatoma, hidradenoma, hondrosarcoma, immunoproliferative small, opoma, ontraocular melanoma, islet cell cancer, Kaposi's sarcoma, kidney cancer, langerhan's cell-histiocytosis, laryngeal cancer, leiomyosarcoma, leukemia, li-fraumeni syndrome, lip cancer, liposarcoma, liver cancer, lung cancer, lymphedema, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leigomyosarcoma, leukemia (e.g. b-cell, mixed cell, null-cell, t-cell, t-cell chronic, htlv-ii-associated, lymphangiosarcoma, lymphocytic acute, lymphocytic chronic, mast-cell and myeloid), leukosarcoma, leydig cell tumor, liposarcoma, leiomyoma, leiomyosarcoma, lymphangioma, lymphangiocytoma, lymphagioma, lymphagiomyoma, lymphangiosarcoma, male breast cancer, malignant- rhabdoid-tumor-of-kidney, medulloblastoma, melanoma, Merkel cell cancer, mesothelioma, metastatic cancer, mouth cancer, multiple endocrine neoplasia, mycosis fungoides, myelodysplastic syndromes, myeloma, myeloproliferative disorders, malignant carcinoid syndrome carcinoid heart disease, medulloblastoma, meningioma, melanoma, mesenchymoma, mesonephroma, mesothelioma, myoblastoma, myoma, myosarcoma, myxoma, myxosarcoma, nasal cancer, nasopharyngeal cancer, nephroblastoma, neuroblastoma, neurofibromatosis, Nijmegen breakage syndrome, non-melanoma skin cancer, non-small-cell-lung-cancer-(nsclc), neurilemmoma, neuroblastoma, neuroepithelioma, neurofibromatosis, neurofibroma, neuroma, neoplasms (e.g. bone, breast, digestive system, colorectal, liver), ocular cancers, oesophageal cancer, oral cavity cancer, oropharynx cancer, osteosarcoma, ostomy ovarian cancer, pancreas cancer, paranasal cancer, parathyroid cancer, parotid gland cancer, penile cancer, peripheral- neuroectodermal-tumors, pituitary cancer,

polycythemia vera, prostate cancer, osteoma, osteosarcoma, ovarian carcinoma, papilloma, paraganglioma, paraganglioma nonchromaffin, pinealoma, plasmacytoma, protooncogene, rare-cancers-and-associated- disorders, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, Rothmund-Thomson syndrome, reticuloendotheliosis, rhabdomyoma, salivary gland cancer, sarcoma, schwannoma, Sezary syndrome, skin cancer, small cell lung cancer (sclc), small intestine cancer, soft tissue sarcoma, spinal cord tumors, squamous-cell-carcinoma-(skin), stomach cancer, synovial sarcoma, sarcoma (e.g. Ewing's experimental, Kaposi's and mast-cell sarcomas), Sertoli cell tumor, synovioma, testicular cancer, thymus cancer, thyroid cancer, transitional-cell-cancer-(bladder), transitional-cell-cancer-(renal-pelvis-/-ureter), trophoblastic cancer, teratoma, theca cell tumor, thymoma, trophoblastic tumor, urethral cancer, urinary system cancer, uroplakins, uterine sarcoma, uterus cancer, vaginal cancer, vulva cancer, Waldenstrom' s-macroglobulinemia and Wilms' tumor.

14. Use according to claim 1 or 10, wherein the non self antigen binding site or anti-cancer antigen antibody binds to a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 3 and 4.

15. Use according to claim 6, wherein the non self antigen binding site binds to any one of the following VEGF, VEGFA, VEGFC, VEGFD, Her-2 or CD20.

16. Use according to claim 1 or 10, wherein when the non self antigen binding site or anti-cancer antigen antibody binds to a $P2X_7$ receptor or fragment thereof, it binds to an epitope that is different from an epitope or an immunogen that is a $P2X_7$ receptor or fragment thereof used to form an immune response.

CLAIMS

1. Use of a $P2X_7$ receptor or fragment thereof in the manufacture of a medicament for minimising the progression of cancer in an individual by forming an immune response in the individual to a P2X7 receptor, wherein the cancer in the individual has been reduced in size, mass or other physical measure by the administration of a non self antigen binding site for the treatment of cancer.

2. Use of claim 1, wherein the individual does not have detectable non self antigen binding sites in circulation.

3. Use of claims 1, wherein the individual does not have detectable cancer.

4. Use of claim 3, wherein the individual has developed an immune response to the non self antigen binding site.

5. Use of claim 1, wherein the individual has received a non self antigen binding site that binds to non-functional $P2X_7$ receptor, but not to functional $P2X_7$ receptor, for treatment of the cancer.

6. Use of any one of the preceding claims, wherein the immune response is formed by providing an immunogen in the individual in the form of a $P2X_7$ receptor, or a fragment of a $P2X_7$ receptor that is capable of inducing an immune response to a $P2X_7$ receptor in the individual.

7. Use according to claim 6, wherein the fragment of a $P2X_7$ receptor has an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 3 and 4.

8. Use of claim 6, wherein the non self antigen binding site received by the individual for treatment of the cancer does not bind to a $P2X_7$ receptor, or a fragment of a $P2X_7$ receptor.

9. Use of claim 6, wherein the immunogen is provided in an initial administration to the individual, thereby forming a response that includes IgM production in the individual.

10. Use of claim 6, wherein the immunogen is provided in an initial administration to the individual, thereby forming a response that includes IgM production, and at a later time, in a

further administration to the initial administration, thereby forming a response that includes IgG production.

11. Use according to claim 6, wherein the non self antigen binding site or anti-cancer antigen antibody is selected from the group consisting of a dAb, Fab, Fd, Fv, $F(ab')_2$, scFv and CDR.

12. Use of a $P2X_7$ receptor or fragment thereof in the manufacture of a first composition and use of a non self antigen binding site in the manufacture of a second composition, the first and second compositions for minimising the progression of cancer in an individual, wherein the first composition is adapted to be administered to the individual after the second composition.

13. Use of an immunogen in the form of a cancer-associated $P2X_7$ receptor or fragment thereof in the manufacture of a medicament for forming a humoral immune response to cancer-associated $P2X_7$ receptors in an individual who has received an anti-cancer antigen antibody for therapy of cancer,

wherein the immune response is formed in the individual at a time where anti-cancer antigen antibody administered for treatment of cancer is at a level or concentration that is substantially undetectable in the individual; and/or

the humoral immune response to cancer –associated $P2X_7$ receptors is formed according to an immunisation schedule whereby the amount of antibody formed in the individual to cancer-associated $P2X_7$ receptor is about 0.1 to 25 mg/kg individual,

wherein the cancer in the individual has been reduced in size, mass or other physical measure by the administration of the non self antigen binding site.

14. Use according to claim 12 or 13, wherein the non self antigen binding site or anti-cancer antigen antibody is selected from the group consisting of a dAb, Fab, Fd, Fv, $F(ab')_2$, scFv and CDR.

15. Use according to claim 14, wherein the fragment of a $P2X_7$ receptor has an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 3 and 4.

16. Use according to claim 1, 12 or 13, wherein the cancer is selected from the group consisting of adenocarcinoma, adenoma, adenofibroma, adenolymphoma, adontoma, AIDS related cancers, acoustic neuroma, acute lymphocytic leukemia, acute myeloid leukemia,

adenocystic carcinoma, adrenocortical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft-part sarcoma, ameloblastoma, angiokeratoma, angiolymphoid hyperplasia with eosinophilia, angioma sclerosing, angiomatosis, apudoma, anal cancer, angiosarcoma, aplastic anaemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma (skin), bladder cancer, bone cancers, bowel cancer, brain stem glioma, brain and CNS tumors, breast cancer, branchioma, CNS tumors, carcinoid tumors, cervical cancer, childhood brain tumors, childhood cancer, childhood leukemia, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancers, cutaneous T-cell lymphoma, carcinoma (e.g. Walker, basal cell, basosquamous, Brown-Pearce, ductal, Ehrlich tumor, Krebs 2, Merkel cell, mucinous, non-small cell lung, oat cell, papillary, scirrhous, bronchiolar, bronchogenic, squamous cell, and transitional cell), carcinosarcoma, cervical dysplasia, cystosarcoma phyllodies, cementoma, chordoma, choristoma, chondrosarcoma, chondroblastoma, craniopharyngioma, cholangioma, cholesteatoma, cylindroma, cystadenocarcinoma, cystadenoma, dermatofibrosarcoma- protuberans, desmoplastic-small-round-cell-tumor, ductal carcinoma, dysgerminoam, endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extra-hepatic bile duct cancer, eye cancer, eye: melanoma, retinoblastoma, fallopian tube cancer, fanconi anaemia, fibroma, fibrosarcoma, gall bladder cancer, gastric cancer, gastrointestinal cancers, gastrointestinal-carcinoid-tumor, genitourinary cancers, germ cell tumors, gestationaltrophoblastic-disease, glioma, gynaecological cancers, giant cell tumors, ganglioneuroma, glioma, glomangioma, granulosa cell tumor, gynandroblastoma, haematological malignancies, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hereditary breast cancer, histiocytosis, Hodgkin's disease, human papillomavirus, hydatidiform mole, hypercalcemia, hypopharynx cancer, hamartoma, hemangioendothelioma, hemangioma, hemangiopericytoma, hemangiosarcoma, hemangiosarcoma, histiocytic disorders, histiocytosis malignant, histiocytoma, hepatoma, hidradenoma, hondrosarcoma, immunoproliferative small, opoma, ontraocular melanoma, islet cell cancer, Kaposi's sarcoma, kidney cancer, langerhan's cell-histiocytosis, laryngeal cancer, leiomyosarcoma, leukemia, li-fraumeni syndrome, lip cancer, liposarcoma, liver cancer, lung cancer, lymphedema, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leigomyosarcoma, leukemia (e.g. b-cell, mixed cell, null-cell, t-cell, t-cell chronic, htlv-ii-associated, lymphangiosarcoma, lymphocytic acute, lymphocytic chronic, mast-cell and myeloid), leukosarcoma, leydig cell tumor, liposarcoma, leiomyoma, leiomyosarcoma, lymphangioma, lymphangiocytoma, lymphagioma, lymphagiomyoma, lymphangiosarcoma,

male breast cancer, malignant- rhabdoid-tumor-of-kidney, medulloblastoma, melanoma, Merkel cell cancer, mesothelioma, metastatic cancer, mouth cancer, multiple endocrine neoplasia, mycosis fungoides, myelodysplastic syndromes, myeloma, myeloproliferative disorders, malignant carcinoid syndrome carcinoid heart disease, medulloblastoma, meningioma, melanoma, mesenchymoma, mesonephroma, mesothelioma, myoblastoma, myoma, myosarcoma, myxoma, myxosarcoma, nasal cancer, nasopharyngeal cancer, nephroblastoma, neuroblastoma, neurofibromatosis, Nijmegen breakage syndrome, non-melanoma skin cancer, non-small-cell-lung-cancer-(nsclc), neurilemmoma, neuroblastoma, neuroepithelioma, neurofibromatosis, neurofibroma, neuroma, neoplasms (e.g. bone, breast, digestive system, colorectal, liver), ocular cancers, oesophageal cancer, oral cavity cancer, oropharynx cancer, osteosarcoma, ostomy ovarian cancer, pancreas cancer, paranasal cancer, parathyroid cancer, parotid gland cancer, penile cancer, peripheral- neuroectodermal-tumors, pituitary cancer, polycythemia vera, prostate cancer, osteoma, osteosarcoma, ovarian carcinoma, papilloma, paraganglioma, paraganglioma nonchromaffin, pinealoma, plasmacytoma, protooncogene, rare-cancers-and-associated- disorders, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, Rothmund-Thomson syndrome, reticuloendotheliosis, rhabdomyoma, salivary gland cancer, sarcoma, schwannoma, Sezary syndrome, skin cancer, small cell lung cancer (sclc), small intestine cancer, soft tissue sarcoma, spinal cord tumors, squamous-cell-carcinoma-(skin), stomach cancer, synovial sarcoma, sarcoma (e.g. Ewing's experimental, Kaposi's and mast-cell sarcomas), Sertoli cell tumor, synovioma, testicular cancer, thymus cancer, thyroid cancer, transitional-cell-cancer-(bladder), transitional-cell-cancer-(renal-pelvis-/-ureter), trophoblastic cancer, teratoma, theca cell tumor, thymoma, trophoblastic tumor, urethral cancer, urinary system cancer, uroplakins, uterine sarcoma, uterus cancer, vaginal cancer, vulva cancer, Waldenstrom' s-macroglobulinemia and Wilms' tumor.

17. Use according to claim 1, 12 or 13, wherein the non self antigen binding site or anti-cancer antigen antibody binds to a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 3 and 4.

18. Use according to claim 8, wherein the non self antigen binding site binds to any one of the following VEGF, VEGFA, VEGFC, VEGFD, Her-2 or CD20.

19. Use according to claim 1, 12 or 13, wherein when the non self antigen binding site or anti-cancer antigen antibody binds to a $P2X_7$ receptor or fragment thereof, it binds to an epitope

that is different from an epitope or an immunogen that is a $P2X_7$ receptor or fragment thereof used to form an immune response.